Disclaimer<\/b><\/p> \n
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.<\/p> \n
关于诺华<\/b><\/p> \n
诺华正在通过创想医药未来以改善人们生活质量、延长人类寿命。作为全球知名的医药健康企业，我们运用创新科学和数字化技术，在医药健康需求增长的领域创造变革性的治疗方法。在探索新药物的过程中，我们不懈创新，对研发的投资一直处于行业全球先列。在全球，超过7.99亿患者受益于诺华产品，同时，我们持续探索更多创新方式使我们的创新疗法造福更多患者。诺华在全球拥有来自超过140个国家的约10.9万名员工。如需更多信息，敬请登录公司网站：www.novartis.com<\/a> 。<\/p> \n 关于诺华中国<\/b><\/p> \n “诺华”中文取意“承诺中华”，即承诺通过不断创新的产品和服务，致力于提高中国人民的健康水平和生活质量。诺华在中国的业务包括诺华肿瘤、诺华制药和山德士，全国建有两大生产基地，并在北京、上海和江苏设立了研发机构。从研发到生产销售，诺华以多元化的业务组合，全面服务中国老百姓的健康。目前，诺华在中国拥有8000多名员工。如需更多信息，敬请登录公司中文网站http:\/\/www.novartis.com.cn<\/a>。<\/p> \n 图片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-a?lang=1<\/a>
图片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-b?lang=1<\/a>
图片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-c?lang=1<\/a>
图片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-d?lang=1<\/a><\/p>"];
$("#dvExtra").html(content_array[0]);})();